Boston, MA -- (ReleaseWire) -- 04/11/2014 -- Global Markets Direct's, 'Crohn's Disease - Pipeline Review, H1 2014', provides an overview of the Crohn's Disease's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
View Full Report Details and Table of Contents
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Crohn's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Crohn's Disease pipeline on the basis of target, MoA, route of administration and molecule type
Companies Mentioned in this Report: Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, Osiris Therapeutics, Inc., Amgen Inc., Sanofi, AstraZeneca PLC, Eli Lilly and Company, Inovio Pharmaceuticals, Inc., Gilead Sciences, Inc., Daiichi Sankyo Company, Limited, AbGenomics International, Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, BioLineRx, Ltd., Celltrion, Inc., Sylentis S.A., Biocon Limited, Eisai Co., Ltd., Pfizer Inc., Teva Pharmaceutical Industries Limited, Sandoz Inc., Celgene Corporation, Toray Industries, Inc., 4SC AG, iCo Therapeutics Inc., Enzo Biochem, Inc., NPS Pharmaceuticals, Inc., Soligenix, Inc., Protalix BioTherapeutics, Inc., ProMetic Life Sciences Inc., Galapagos NV, CIMAB S.A., Alba Therapeutics Corporation, Farmacija d.o.o. Tuzla, Pieris AG, Neovacs SA, Viropro Inc., Oncodesign SA, Tillotts Pharma AG, Allozyne, Inc., Zealand Pharma A/S, NovImmune SA, TxCell SA, Selexys Pharmaceuticals Corporation, Effimune SAS, ChemoCentryx, Inc., Giuliani S.p.A., Winston Pharmaceuticals, Inc., S.L.A. Pharma AG, Medestea Research & Production S.p.A., Stelic Institute & Co., Janssen Research & Development, LLC, Antibe Therapeutics, Inc., CLL Pharma, Amunix, Inc., Protagonist Therapeutics Inc., Alfa Wassermann S.p.A, Altheus Therapeutics, Inc., Sigmoid Pharma Ltd., Ampio Pharmaceuticals, Inc., Advancell, Genor BioPharma Co., Ltd., Aprogen, Inc., RedHill Biopharma Ltd., Selvita S.A, Ensemble Therapeutics Corporation, Inbiopro Solutions Pvt. Ltd., Enlivex Therapeutics Ltd, Immune Response BioPharma, Inc., Qu Biologics Inc., Oncobiologics, Inc., Curaxys, S.L., Innovent Biologics, Inc., AbbVie Inc., Trino Therapeutics Ltd, Aniona ApS, ChironWells GmbH, Epirus Biopharmaceuticals, Inc., AlphaMab Co., Ltd, Calypso Biotech SA, Pharmapraxis, GT Biologics Limited
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Parkinson's Disease - Pipeline Review, H1 2014
- Alzheimer's Disease - Pipeline Review, H1 2014
- Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014
- Huntington's Disease - Pipeline Review, H1 2014
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014
- Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2014
- Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2014
- Batten Disease - Pipeline Review, H1 2014
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H1 2014